Randomised control trials comparing oral vitamin K antagonists with low molecular weight heparin
| Recurrent venous thromboembolism, Warfarin:LWMH | (Calculated from combined endpoint minus bleeding) 3/75 (4%): 2/71 (2.8%) | 53/336 (15.8%): 27/336 (8%) | At 3 months: 10/100(10%): 6/100 (6%) |
|---|---|---|---|
| At 1 year: 16/100 (16%): 7/100 (7%) | |||
| Bleeding, Warfarin:LMWH | Major: 12/75 (16%): 5/71 (7%) | Major: 12/335 (4%): 19/335 (6%) | At 3 months: 24/100 (24%): 27/100 (27%) |
| Advanced cancer indices | Metastatic disease: 52% | Performance status 3, 4 and Weight<40 kg excluded | Excluded if <3 months prognosis |
| <3 month prognosis excluded | |||
| Excluded if <3 month prognosis | Metastatic disease 67% | Metastatic disease: warfarin 36%; LMWH 47% | |
| LMWH regime | Enoxaparin (1.5 mg/kg) | Dalteparin 200 IU/kg for 1 month then 150 IU for 5 months | Tinzaparin (175 IU/kg) |
| Study | Meyer22 | Lee21 | Hull19 |